Impact of Immune Status on Secondary Infections in Patients With Acute Respiratory Failure
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 686
- 试验地点
- 2
- 主要终点
- Natural killer cells Cells (CD16 pos)
研究概览
简要总结
This is a retrospective observational study over the period 1/2019 - 02/2024 with the aim of identifying patients with a predisposition to secondary infections.
详细描述
As a reference center, Charité Universitaetsmedizin Berlin has been treating patients with the most severe form of acute respiratory failure, known as acute respiratory distress syndrome (ARDS), for more than 30 years. Despite lung-protective forms of ventilation and the use of extracorporeal procedures for oxygenation and decarboxylation (ECMO), mortality is around forty percent. In addition to the primary cause of ARDS, further infectious complications often develop during the course of the disease, which delay recovery.
The aim of this study is to investigate infectious complications (ventilator-associated pneumonia, reactivation of Herpes viridae, pathogen resistance despite formally correct therapy, fungal infections) depending on the immune status.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 7 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female acute respiratory distress syndrome patients who had an immune status within 48 h of admission
- •Patients who received intensive care treatment for acute respiratory distress syndrome ward 8i at Charité in the period from 01/2019 to 02/2024 with a maximum follow-up period of 90 days
排除标准
- 未提供
结局指标
主要结局
Natural killer cells Cells (CD16 pos)
时间窗: 01/2019- 02/2024
Absolute number per nanoliter and percentage of lymphocytes.
HLA-DR expression on monocytes
时间窗: 01/2019- 02/2024
in molecules per cell
Herpes simplex reactivation
时间窗: 01/2019- 02/2024
semi-quantitatively with Herpes simplex (negative / slightly positive / positive and strongly positive) in blood or bronchial lavage
B cells (CD19 positive)
时间窗: 01/2019- 02/2024
Absolute number per nanoliter and percentage of lymphocytes
Cytomegalovirus reactivation
时间窗: 01/2019- 02/2024
as absolute copy number per milliliter of blood or bronchioalveolar lavage
Cytotoxic T cells (CD8)
时间窗: 01/2019- 02/2024
Absolute number per nanoliter and percentage of lymphocytes
Epstein Barr virus reactivation
时间窗: 01/2019- 02/2024
absolute copy number per milliliter of blood or bronchioalveolar lavage
T helper cells (CD4)
时间窗: 01/2019- 02/2024
Aabsolute number per nanoliter and percentage of lymphocytes
Herpes simplex reactivation
时间窗: 01/2019- 12/2025
semi-quantitatively with Herpes simplex (negative / slightly positive / positive and strongly positive) in blood or bronchial lavage
Cytomegalovirus reactivation
时间窗: 01/2019- 12/2025
as absolute copy number per milliliter of blood or bronchioalveolar lavage
Epstein Barr virus reactivation
时间窗: 01/2019- 12/2025
absolute copy number per milliliter of blood or bronchioalveolar lavage
B cells (CD19 positive)
时间窗: 01/2019- 12/2025
Absolute number per nanoliter and percentage of lymphocytes
Natural killer cells Cells (CD16 pos)
时间窗: 01/2019- 12/2025
Absolute number per nanoliter and percentage of lymphocytes.
T helper cells (CD4)
时间窗: 01/2019- 12/2025
Aabsolute number per nanoliter and percentage of lymphocytes
Cytotoxic T cells (CD8)
时间窗: 01/2019- 12/2025
Absolute number per nanoliter and percentage of lymphocytes
HLA-DR expression on monocytes
时间窗: 01/2019- 12/2025
in molecules per cell
次要结局
- Pathogen persistence after guideline-compliant therapy (yes/no)(01/2019- 02/2024)
- Catecholamine doses(01/2019- 02/2024)
- Number of catecholamine days(01/2019- 02/2024)
- Recording of end organ damage such as liver and kidney failure(01/2019- 02/2024)
- Costs of treatment(01/2019- 02/2024)
- Ventilator-associated pneumonia (yes/no)(01/2019- 02/2024)
- Concomitant infections with therapy(01/2019- 02/2024)
- Volumes(01/2019- 02/2024)
- Diagnoses during the intensive care stay(01/2019- 02/2024)
- Administration of immunosuppressants(01/2019- 02/2024)
- Extracorporeal membrane oxygenation duration(01/2019- 02/2024)
- Occurrence of fungal pneumonia (yes/no)(01/2019- 02/2024)
- Simplified Acute Physiology Score (SAPS II)(01/2019- 02/2024)
- Beginn weaning(01/2019- 02/2024)
- Ventilation parameters(01/2019- 02/2024)
- Mortality(01/2019- 02/2024)
- Sequential Organ Failure Assessment (SOFA score)(01/2019- 02/2024)
- Pre-existing conditions(01/2019- 02/2024)
- Beginn weaning(01/2019- 12/2025)
- Extracorporeal membrane oxygenation duration(01/2019- 12/2025)
- Costs of treatment(01/2019- 12/2025)
- Pathogen persistence after guideline-compliant therapy (yes/no)(01/2019- 12/2025)
- Ventilator-associated pneumonia (yes/no)(01/2019- 12/2025)
- Occurrence of fungal pneumonia (yes/no)(01/2019- 12/2025)
- Mortality(01/2019- 12/2025)
- Sequential Organ Failure Assessment (SOFA score)(01/2019- 12/2025)
- Simplified Acute Physiology Score (SAPS II)(01/2019- 12/2025)
- Pre-existing conditions(01/2019- 12/2025)
- Concomitant infections with therapy(01/2019- 12/2025)
- Volumes(01/2019- 12/2025)
- Ventilation parameters(01/2019- 12/2025)
- Catecholamine doses(01/2019- 12/2025)
- Number of catecholamine days(01/2019- 12/2025)
- Recording of end organ damage such as liver and kidney failure(01/2019- 12/2025)
- Diagnoses during the intensive care stay(01/2019- 12/2025)
- Administration of immunosuppressants(01/2019- 12/2025)
研究者
Claudia Spies
Head of the Department of Anesthesiology and Intensive Care Medicine (CCM/CVK)
Charite University, Berlin, Germany